This company listing is no longer active
2CX Stock Overview
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
ChemoCentryx, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$51.89 |
52 Week High | US$52.79 |
52 Week Low | US$15.40 |
Beta | 1.23 |
1 Month Change | 1.27% |
3 Month Change | 143.79% |
1 Year Change | 78.99% |
3 Year Change | 668.74% |
5 Year Change | 815.01% |
Change since IPO | 536.69% |
Recent News & Updates
Recent updates
Shareholder Returns
2CX | DE Biotechs | DE Market | |
---|---|---|---|
7D | -0.9% | 2.8% | -0.03% |
1Y | 79.0% | 38.7% | 5.5% |
Return vs Industry: 2CX exceeded the German Biotechs industry which returned -16.5% over the past year.
Return vs Market: 2CX exceeded the German Market which returned -27.1% over the past year.
Price Volatility
2CX volatility | |
---|---|
2CX Average Weekly Movement | 29.9% |
Biotechs Industry Average Movement | 5.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2CX's share price has been volatile over the past 3 months.
Volatility Over Time: 2CX's weekly volatility has increased from 17% to 30% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 178 | n/a | https://www.chemocentryx.com |
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis.
ChemoCentryx, Inc. Fundamentals Summary
2CX fundamental statistics | |
---|---|
Market cap | €3.81b |
Earnings (TTM) | -€135.70m |
Revenue (TTM) | €38.01m |
100.3x
P/S Ratio-28.1x
P/E RatioIs 2CX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2CX income statement (TTM) | |
---|---|
Revenue | US$37.28m |
Cost of Revenue | US$71.86m |
Gross Profit | -US$34.58m |
Other Expenses | US$98.51m |
Earnings | -US$133.09m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.85 |
Gross Margin | -92.76% |
Net Profit Margin | -357.01% |
Debt/Equity Ratio | 10.5% |
How did 2CX perform over the long term?
See historical performance and comparison